An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements

• Published in: APL bioengineering Vol. 1; no. 1; p. 016101
• Main Authors: Campelo, Sabrina, Valerio, Massimo, Ahmed, Hashim U., Hu, Yipeng, Arena, Sara L., Neal, Robert E., Emberton, Mark, Arena, Christopher B.
• Format: Journal Article
• Language: English
• Published: United States AIP Publishing LLC 01.12.2017
• ISSN: 2473-2877; 2473-2877
• DOI: 10.1063/1.5005828

Irreversible electroporation (IRE) is an emerging cancer treatment that utilizes non-thermal electric pulses for tumor ablation. The pulses are delivered through minimally invasive needle electrodes inserted into the target tissue and lead to cell death through the creation of nanoscale membrane defects. IRE has been shown to be safe and effective when performed on tumors in the brain, liver, kidneys, pancreas, and prostate that are located near critical blood vessels and nerves. Accurate treatment planning and prediction of the ablation volume require a priori knowledge of the tissue-specific electric field threshold for cell death. This study addresses the challenge of defining an electric field threshold for human prostate cancer tissue. Three-dimensional reconstructions of the ablation volumes were created from one week post-treatment magnetic resonance imaging (MRIs) of ten patients who completed a clinical trial. The ablation volumes were incorporated into a finite element modeling software that was used to simulate patient-specific treatments, and the electric field threshold was calculated by matching the ablation volume to the field contour encompassing the equivalent volume. Solutions were obtained for static tissue electrical properties and dynamic properties that accounted for electroporation. According to the dynamic model, the electric field threshold was 506 ± 66 V/cm. Additionally, a potentially strong correlation (r = −0.624) was discovered between the electric field threshold and pre-treatment prostate-specific antigen levels, which needs to be validated in higher enrollment studies. Taken together, these findings can be used to guide the development of future IRE protocols.